maritide weight loss - Search News

News

Mounjaro, Weight Loss and Help

Not Wegovy or Mounjaro Or Ozempic: This New Monthly Weight Loss Jab Helped People Drop 20% Body Fat

A new monthly weight loss drug, MariTide, helped people shed up to 20% of body weight in a Phase 2 trial—comparable to Wegovy and Mounjaro, but with fewer doses.

The Independent on MSN · 21h

Trial finds weight loss drug taken monthly helps people lose 20% of body weight – but adverse GI events were ‘common’

Trial finds weight loss drug taken monthly helps people lose 20% of body weight – but adverse GI events were ‘common’ - The new drug may rival other weight loss medications such as Ozempic and Mounjar

LADbible · 1d

Ozempic and Mounjaro have new competitor as trial sees people lose 20% of body weight in one year

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly basis rather than weekly.

1don MSN

Amgen experimental weight-loss drug needs lower dose to limit side effects

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Applied Clinical Trials Online22h

MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

New data shows just how powerful the next weight-loss drugs may be

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

17h

Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

1don MSN

New once-a-month drug could treat diabetes and obesity, scientists say

A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and ...

Fierce Biotech22h

Amgen rolls out phase 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

STAT1d

Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

4don MSN

Lilly, Novo, and Amgen set for key obesity trial readouts at upcoming ADA event

Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results